U.S. markets close in 2 hours 28 minutes

Cabaletta Bio, Inc. (CABA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.0300-0.0150 (-1.44%)
As of 01:29PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close1.0450
Bid1.0200 x 1400
Ask1.0400 x 900
Day's Range1.0000 - 1.0400
52 Week Range0.9000 - 14.9500
Avg. Volume153,424
Market Cap29.846M
Beta (5Y Monthly)1.53
PE Ratio (TTM)N/A
EPS (TTM)-1.8350
Earnings DateAug 03, 2022 - Aug 08, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for CABA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Cabaletta Bio, Inc.
    Daily – Vickers Top Buyers & Sellers for 05/02/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • Zacks

    What Makes Cabaletta Bio, Inc. (CABA) a New Buy Stock

    Cabaletta Bio, Inc. (CABA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

  • Benzinga

    Why Did Mizuho Cut Price Target On This CAR-T Stock, But Remain Bullish

    Mizuho met Cabaletta Bio Inc (NASDAQ: CABA) management team after last week's data release at ASGCT. Although, the data readout at ASGCT failed to cheer investors, and shares lost almost 16% during the market trading session. Mizuho reiterates a Buy rating on CABA shares but lowers the price target to $10 (down from $20) due to a higher discount rate reflecting the current economic environment and increased financing risk. The analyst writes that the safety data to date and the persistence of en

  • Benzinga

    Cabaletta Bio's Updated Interim DSG3-CAART Data Fails To Cheer Investors

    Cabaletta Bio Inc (NASDAQ: CABA) presented updated data from the DesCAARTes trial, evaluating DSG3-CAART in adults with mucosal-dominant pemphigus vulgaris (mPV), a blistering skin disease that affects mucous membranes. No dose-limiting toxicities were observed within three months of DSG3-CAART infusion through cohort A4 (2.5 billion cells). There was a dose-dependent increase in DSG3-CAART persistence through day 29 in cohorts A1 to A4, indicating that DSG3-CAART cells were not eliminated throu